Twist Bioscience (NASDAQ:TWST) Stock Price Up 8%

Twist Bioscience Co. (NASDAQ:TWST) shares traded up 8% during trading on Tuesday . The company traded as high as $31.81 and last traded at $31.81. 105,794 shares were traded during mid-day trading, a decline of 88% from the average session volume of 907,955 shares. The stock had previously closed at $29.45.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Scotiabank boosted their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a report on Monday, February 5th. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and increased their target price for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th.

Twist Bioscience Trading Up 6.2 %

The firm has a market capitalization of $1.81 billion, a P/E ratio of -8.81 and a beta of 1.62. The stock’s 50-day simple moving average is $35.26 and its 200-day simple moving average is $30.22.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. During the same quarter in the previous year, the company posted ($0.74) earnings per share. The firm’s revenue was up 31.8% compared to the same quarter last year. On average, equities research analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at approximately $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Insiders have sold a total of 11,037 shares of company stock worth $384,092 over the last ninety days. 3.92% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently modified their holdings of the business. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares during the last quarter. Artisan Partners Limited Partnership grew its position in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after buying an additional 1,961,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Twist Bioscience by 2.9% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Nikko Asset Management Americas Inc. raised its position in Twist Bioscience by 2.9% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Twist Bioscience by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.